**Service Specification No.** 170012/S

**Service**
Proton Beam Therapy Service (Adults and Children)

**Commissioner Lead**
Highly Specialised Commissioning, NHS England

**Provider Lead**
N/A

**Period**
1st April 2017 – 31st March 2020

**Date of Review**
October 2019.

### 1. Population Needs

#### 1.1 National/local context and evidence base

1.1.1. Proton Beam Therapy (PBT) provides radiation by delivering a beam of proton particles, rather than by external beam radiotherapy (EBRT) using X-Rays. PBT facilitates the safe use of controlled doses of ionising radiation to treat people who have cancer with the aim of delivering as high a dose of radiation as possible to the cancer, whilst sparing the surrounding normal tissues. A phenomenon known as the Bragg Peak means that almost no radiation dose is deposited in the normal tissue beyond the tumour. This is in contrast to X-rays where there is dose extension beyond the tumour, reducing as the beam diverges and attenuates.

1.1.2. PBT can be used alone or as part of a multi-modality treatment regime with surgery and /or chemotherapy. PBT is complex and requires an understanding of the principles of medical physics, radiobiology, radiation safety, dosimetry, radiation treatment planning, simulation and interaction of radiation with other treatment modalities.

1.1.3. PBT is a treatment that is given with curative intent. Its use can reduce some acute toxicity and more significantly can reduce the long term permanent side effects of treatment and improve the chances of maintaining quality of life. PBT can also be used as part of a dose escalation strategy to increase tumour control, by sparing critical structures. It is typically delivered to patients every weekday, over a number of weeks, depending on the tumour site. Most patients are treated on an outpatient basis.

1.1.4. PBT is a highly complex technology that is still undergoing rapid technical advances. Rigorous quality standards are thus essential. The core group of patients for whom benefit has a strong evidence base are also complicated and require integration with the infrastructure of a major cancer centre, including highly specialist surgery and cancer services. There is a need to...
accompany PBT with robust outcomes assessment. For all these reasons undertaking PBT within a major cancer centre, linked to an academic oncology and medical physics framework is ideal.

1.2 Proton Overseas Programme

1.2.1 Proton beam therapy has been offered to all clinically appropriate patients in England since 2008 through the NHS Proton Beam Programme. NHS England will continue to do so in line with agreed clinical policies for the duration specified.

1.3 NHS Proton Beam Therapy Service

1.3.1 In 2009, planning began on the development of an NHS Proton Beam Therapy service. Two PBT centres have been commissioned by the Department of Health and NHS England at The Christie NHS Foundation Trust in Manchester and University College London Hospitals NHS Foundation Trust in London.

1.3.2 It is anticipated that when the NHS service starts it will still be necessary for some patients requiring PBT to continue to be sent for treatment abroad. This is to allow the NHS service to increase its clinical expertise and capacity in a safe and controlled manner.

2. Outcomes

2.1 NHS Outcomes Framework Domains & Indicators

<table>
<thead>
<tr>
<th>Domain</th>
<th>Preventing people from dying prematurely</th>
<th>X</th>
</tr>
</thead>
<tbody>
<tr>
<td>Domain 2</td>
<td>Enhancing quality of life for people with long-term conditions</td>
<td>X</td>
</tr>
<tr>
<td>Domain 3</td>
<td>Helping people to recover from episodes of ill-health or following injury</td>
<td>X</td>
</tr>
<tr>
<td>Domain 4</td>
<td>Ensuring people have a positive experience of care</td>
<td>X</td>
</tr>
<tr>
<td>Domain 5</td>
<td>Treating and caring for people in safe environment and protecting them from avoidable harm</td>
<td>X</td>
</tr>
</tbody>
</table>

2.2 Local defined outcomes

The Programme aims to deliver:

- improved cancer survival and cure rates
- delivery of accurately targeted therapeutic doses of radiation to tumours
- ability to minimise and reduce the short and long-term side effects of treatment
- maintenance of good patient (and family) experience of treatment
- maintenance of safe integration with other aspects of treatment and interventions within the
clinical pathway of care

- development of clear clinical outcome information to support further clinical and service development
- development of the UK based service, infrastructure, clinical protocols and pathways of care.

2.3 Provider Outcomes

The provider must:

- have a structured clinical outcomes collection and analysis programme
- collect relevant diagnosis specific data on clinical outcome measures
  - overall survival
  - progression free survival
  - tumour local control
  - acute and late toxicity
- collect patient satisfaction and patient experience data and demonstrate how this has been acted upon.
- describe links to clinical trials, national registries and academic studies.

3. Scope

3.1 Aims and objectives of service

Aims

3.1.1 The aim of the service is to provide high energy proton beam therapy services for adult, teenage and young adult (age 16 – 24 years), and paediatric patients (age < 16 years), overseas to improve cancer outcomes, reduce morbidity arising from treatment, and support the patient and family throughout their cancer journey and beyond.

Objectives

3.1.2 The objective of the Proton Overseas Programme service is that:

- all eligible patients that can safely travel overseas without compromise to other aspects of care and outcomes, are able and willing to do so receive PBT at the recognised high quality treatment providers overseas commissioned by NHS England.

3.2 Service description/care pathway

3.2.1 In addition to the standards required within the Contract, specific quality standards and measures will be expected. The provider must:

Facilities and equipment
**Essential**

- meet technical standards in accordance with the equipment specification and equipment supplier's service delivery model
- ensure modern equipment is used including image guidance (MRI, CT scanner), treatment planning system tools and Oncology Information Systems
- be fully integrated with a conventional radiotherapy programme and department
- have a minimum of two rooms and two full gantries (or equivalent)
- have full patient immobilisation systems available
- have contingency plans and contracts in place for patient treatment to continue in the event of technical interruptions and/or breakdown.

**Desirable**

- be able to deliver passive and active (spot scanning) Intensity Modulated Proton Therapy (IMPT) Proton modalities
- have the PBT centre situated within a Hospital campus
- have in-patient and out-patient care on the same campus/site available.

**Staffing**

**Essential**

- ensure all staff delivering PBT are adequately trained and have the appropriate skills and competencies to do so
- ensure adequate site specialist oncology staff with links to integrated Multi-Disciplinary Teams (MDTs)
- meet the national standards for training and practice of the relevant professional bodies (equivalent to for example Royal College of Radiologists (RCR), Society and College of Radiographers (SCoR) and Institute of Physics and Engineering in Medicine (IPEM))
- demonstrate processes for the management of risk to staff
- support the development of the UK PBT service by, for example, making provision by agreement for training placements for UK PBT clinicians and technicians.

**Clinical standards and pathways**

**Essential**

- provide assurance that radiotherapy is delivered according to national and international standards where appropriate and applicable
- provide assurance that their services match standards for Radiotherapy, that are consistent with the Cancer Reform Strategy Commitment to develop World Class services and the NHS England Vision for Radiotherapy Services (2014)
• be accredited by national and/or state regulatory board
• participate in national quality assurance programme
• have treatment capacity and administrative processes to be able to accept patients within a timescale to allow pathways that meet clinically relevant start-to-radiotherapy target times (will vary according to tumour)
• ensure the safe treatment of patients in accordance with agreed protocols
• demonstrate processes for the management of risk to patients
• have dedicated programmes for children, teenagers & young adults and adults e.g. base of skull
• deliver care in settings appropriate to age
• take a lead in engagement with appropriate multi-disciplinary diagnostic and treatment teams
• provide full interdisciplinary care (Paediatric Oncology, Anaesthesia, Endocrine, Head & Neck Surgery, Neurosurgery)
• provide supportive therapy including chemotherapy, emergency management and tumour multi-disciplinary teams
• make provision for psychosocial multi-disciplinary teams
• use effective communication pathways between the referring treatment centre multi-disciplinary team and the overseas provider multi-disciplinary team
• provide treatment summaries back to the referring centres on completion of treatment within two weeks of completion of treatment
• enter patients prospectively into local or national registry and outcome evaluation programmes
• collaborate with UK data collection on treatment details, clinical outcomes and transfer of full RTDICOM data, for NHS England Overseas programme to be able to store and analyse
• provide treatment to patients in accordance with the nationally agreed (NCRI, CCL, CSG and NHRC) clinical trial protocols within the UKCRN Study Portfolio and guidelines (CCLG) where these exist
• have a record of presenting practice and outcomes in national and international conferences, specialist meetings and in peer reviewed publications.

Desirable
• have formal links or form part of an Academic/University centre.

Patients

Essential
• ensure protection of children and other vulnerable people in line with national standards (equivalent to “Safeguarding Vulnerable People in the Reformed NHS: Accountability and
• have case/patient management/concierge service to facilitate patient pathways and referrals including arranging accommodation and providing day to day support to families and carers of PBT patients whilst receiving treatment

• provide patients with information appropriate to their needs and treatment pathway.

Paediatric Specific

Essential

• have a throughput of over 70 paediatric cases per annum

• anaesthesia services used has minimum throughput of over 30 sedated paediatric cases per annum (across all specialities).

• ensure outpatient specialist paediatric anaesthesia is available for all patients if required, including deep i.v. sedation (standard) or full narcosis with intubation, induction and recovery rooms

• ensure Play therapy access is available for all patients

• be formally connected to high-volume Paediatric Oncology department ideally on the same campus and within the same organisational framework

• participate in multicentre, multidisciplinary clinical trials e.g. SIOP links

• ensure that the paediatric service has formal specialist academic leadership and links

• ensure specialised Paediatric Oncologists supervising appropriate children at least weekly and ideally within the PBT centre.

3.3 Population covered

• For further information see clinical commissioning policies for:
  o Proton Beam Radiotherapy Paediatric Cancer Treatment
  o Proton Beam Radiotherapy for Teenagers and Young Adult Cancer Treatment
  o Proton Beam Radiotherapy for Adult Cancer Treatment

http://www.england.nhs.uk/commissioning/spec-services/npc-crg/group-b/b01/

3.4 Any acceptance and exclusion criteria and thresholds

• For further information see clinical commissioning policies for:
  o Proton Beam Radiotherapy Paediatric Cancer Treatment
  o Proton Beam Radiotherapy for Teenagers and Young Adult Cancer Treatment
  o Proton Beam Radiotherapy for Adult Cancer Treatment

• The provider may withdraw treatment and refer the patient back to the referring centre if the
patient is considered not to be complying with their treatment regime. Prior to any treatment withdrawal, the provider must have discussed this with the patient and the referring centre, explaining the reasons for treatment withdrawal and actions the patient and/or referring centre need to take. The provider must inform NHS England when treatment is withdrawn and actions taken to prevent and mitigate this action.
Referral Pathway

Site specific referral centre MDT

Referring Centre Clinical Oncology Consultation with patient

Referral made to Proton Clinical Reference Panel (to include full dataset and imaging)

Specific Proton Clinical Reference Panel makes recommendation

NHSE commissioning decision on recommendation

IFR

Approved

Not Approved

Letter sent to referring centre confirming approval and/or any conditions, e.g. further surgery

Letter sent to overseas PBT centre confirming approval

Overseas treatment provider accepts/rejects referral

Patient accepted for treatment

Patient not accepted for treatment

Patient agrees to treatment overseas

Patient refuses treatment overseas

Treat locally

Original referring centre makes referral to overseas provider
Patient Care Pathway

Referral pathway for Proton Overseas Programme.
Patient referral approved & accepted. Patient willing to be treated overseas

Referring Centre makes travel & support arrangements with overseas provider

Referring Centre liaises with overseas provider re treatment dates, current treatment plan, sends images etc

Patient travels to overseas provider

Patient receives PBT at overseas provider as per protocol

Patient returns to UK on completion of treatment

On completion of treatment, the overseas provider sends treatment summary and discharge information to Referring Centre

Patient ongoing treatment continues in UK
### 3.5 Interdependencies with other services/providers

- Oncology – paediatric and adult
- Anaesthesia – paediatric only (minimum throughput of over 30 sedated paediatric cases per annum)
- Endocrinology
- Head & neck surgery
- Neurosurgery
  - Paediatric neurosurgery
  - Specialist skull-based neurosurgical unit
  - Specialist spinal surgical unit
- Chemotherapy
- Emergency Care
- Play therapy – paediatric only
- Accommodation for patients and carers
  
  See Clinical commissioning policy – funding policy for travel and accommodation proton overseas programme
  
  https://www.england.nhs.uk/commissioning/spec-services/npc-crg/group-b/b01/
- Support services for patients and carers
- Established links with (or part of) University/Academic centre.

### 4. Applicable Service Standards

Refer to section 3.2 service description for service standards

- Demonstrate processes for the management of risk to patients and staff
- The provider will notify the Chair of the Proton Overseas Panel of any ‘never events’ or serious untoward incidents (see main contract body for definitions) within 48 hours of the event occurring.

#### 4.1 Applicable national standards e.g. NICE

- Equivalent national standards where applicable for Radiation Protection
- Services should match international standards for Radiotherapy, that are consistent with the Cancer Reform Strategy Commitment to develop World Class services and the NHS England Vision for Radiotherapy Services (2014)
- Be accredited by national and/or state regulatory board
• Provide treatment to patients in accordance with the nationally agreed (NCRI, CCL, CSG and NHRC) clinical trial protocols within the UKCRN Study Portfolio and guidelines (CCLG) where these exist


4.2 Applicable standards set out in Guidance and/or issued by a competent body (e.g. Royal Colleges)
• Meet the national standards of the relevant professional bodies (equivalent to for example Royal College of Radiologists (RCR), Society and College of Radiographers (SCoR) and Institute of Physics and Engineering in Medicine (IPEM)).

5. Applicable quality requirements and CQUIN goals

5.1 Applicable quality requirements (See Schedule 4 Parts A-D)
Refer to section 3.2 service description for service standards
• recognised UK clinical oncology experts to visit and assess clinical quality including patterns of integrated care
• the provider will have a recognised system to demonstrate service quality and standards
• the service will have detailed clinical protocols setting out nationally (and local where appropriate) recognised good practice for each treatment site
• the quality system and its treatment protocols will be subject to regular clinical and management audit
• the provider is required to undertake regular patient surveys and develop and implement an action plan based on findings.

5.2 Applicable CQUIN goals (See Schedule 4 Part E)
Not applicable

6. Location of Provider Premises

The Provider’s Premises are located at:
N/A
Appendix Two

Quality standards specific to the service using the following template:

Proton Beam Quality Indicators
These should be read in conjunction with the national service specification and extended version of the indicators.

<table>
<thead>
<tr>
<th>Number</th>
<th>Indicator</th>
<th>Data source</th>
<th>Domains</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBT-16-001</td>
<td>Process for the commissioning of new equipment</td>
<td>Self declaration</td>
<td>1,2</td>
</tr>
<tr>
<td>PBT-16-002</td>
<td>Use of equipment and technologies</td>
<td>Self declaration</td>
<td>5</td>
</tr>
<tr>
<td>PBT-16-003</td>
<td>Treatment capacity</td>
<td>Self declaration</td>
<td>5</td>
</tr>
<tr>
<td>PBT-16-004</td>
<td>There is a minimum of 2 treatment rooms</td>
<td>Self declaration</td>
<td>5</td>
</tr>
<tr>
<td>PBT-16-005</td>
<td>There are contingency plans for technical interruptions /breakdown</td>
<td>Self declaration</td>
<td>5</td>
</tr>
<tr>
<td>PBT-16-006</td>
<td>Access to conventional radiotherapy</td>
<td>Self declaration</td>
<td>5</td>
</tr>
<tr>
<td>PBT-16-007</td>
<td>Access to inpatient and outpatient care</td>
<td>Self declaration</td>
<td>5</td>
</tr>
<tr>
<td>PBT-16-008</td>
<td>Provision of interdisciplinary care</td>
<td>Self declaration</td>
<td>3, 5</td>
</tr>
<tr>
<td>PBT-16-009</td>
<td>Provision of supportive services</td>
<td>Self declaration</td>
<td>3, 5</td>
</tr>
<tr>
<td>PBT-16-010</td>
<td>Communication pathways</td>
<td>Self declaration</td>
<td>4, 5</td>
</tr>
<tr>
<td>PBT-16-011</td>
<td>Staffing levels and training</td>
<td>Self declaration</td>
<td>5</td>
</tr>
<tr>
<td>PBT-16-012</td>
<td>Dedicated site specialised teams</td>
<td>Self declaration</td>
<td>1,2,3</td>
</tr>
<tr>
<td>PBT-16-013</td>
<td>The service is delivered according to national and international standards</td>
<td>Self declaration</td>
<td>5</td>
</tr>
<tr>
<td>PBT-16-014</td>
<td>Treatment protocols</td>
<td>Self declaration</td>
<td>5</td>
</tr>
<tr>
<td>Number</td>
<td>Indicator</td>
<td>Data source</td>
<td>Domains</td>
</tr>
<tr>
<td>----------</td>
<td>----------------------------------------------------</td>
<td>---------------</td>
<td>---------</td>
</tr>
<tr>
<td>PBT-16-015</td>
<td>National/state regulatory accreditation</td>
<td>Self declaration</td>
<td>5</td>
</tr>
<tr>
<td>PBT-16-016</td>
<td>Quality assurance</td>
<td>Self declaration</td>
<td>5</td>
</tr>
<tr>
<td>PBT-16-017</td>
<td>Risk management</td>
<td>Self declaration</td>
<td>5</td>
</tr>
</tbody>
</table>

Outcomes/quantitative indicators

<table>
<thead>
<tr>
<th>Number</th>
<th>Indicator</th>
<th>Data source</th>
<th>Domains</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBT-16-018</td>
<td>Participation in clinical audit</td>
<td>Self declaration</td>
<td>2</td>
</tr>
<tr>
<td>PBT-16-019</td>
<td>Research and academic practice</td>
<td>Self declaration</td>
<td>2</td>
</tr>
</tbody>
</table>

Patient Experience

<table>
<thead>
<tr>
<th>Number</th>
<th>Indicator</th>
<th>Data source</th>
<th>Domains</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBT-16-020</td>
<td>Safeguarding of children and vulnerable people</td>
<td>Self declaration</td>
<td>4, 5</td>
</tr>
<tr>
<td>PBT-16-021</td>
<td>Patient management/ concierge service</td>
<td>Self declaration</td>
<td>4</td>
</tr>
<tr>
<td>PBT-16-022</td>
<td>Patient information</td>
<td>Self declaration</td>
<td>4</td>
</tr>
<tr>
<td>PBT-16-023</td>
<td>Care settings</td>
<td>Self declaration</td>
<td>4</td>
</tr>
</tbody>
</table>

Paediatric Specific
Structure & Process

<table>
<thead>
<tr>
<th>Number</th>
<th>Indicator</th>
<th>Data source</th>
<th>Domains</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBT-16-024</td>
<td>Minimum activity</td>
<td>Self declaration</td>
<td>5</td>
</tr>
<tr>
<td>PBT-16-025</td>
<td>Outpatient specialist paediatric anaesthesia</td>
<td>Self declaration</td>
<td>5</td>
</tr>
<tr>
<td>PBT-16-026</td>
<td>Play Therapy</td>
<td>Self declaration</td>
<td>4</td>
</tr>
<tr>
<td>Number</td>
<td>Indicator</td>
<td>Data source</td>
<td>Domains</td>
</tr>
<tr>
<td>----------</td>
<td>-----------------------------------------------------</td>
<td>---------------------</td>
<td>---------</td>
</tr>
<tr>
<td>PBT-16-027</td>
<td>Access to paediatric oncology</td>
<td>Self declaration</td>
<td>5</td>
</tr>
<tr>
<td>PBT-16-028</td>
<td>Specialised paediatric oncologist provision</td>
<td>Self declaration</td>
<td>5</td>
</tr>
</tbody>
</table>

Outcomes/quantitative indicators

<table>
<thead>
<tr>
<th>Number</th>
<th>Indicator</th>
<th>Data source</th>
<th>Domains</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBT-16-029</td>
<td>Research and academic links</td>
<td>Self declaration</td>
<td>2</td>
</tr>
</tbody>
</table>